| Document |
Document Title |
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
|
WO/2021/082997A1 |
An amide compound containing a substituted acetophenone structure fragment, having a structure shown as general formula I. Please see the description for the definitions of substituents in the formula. The compound has a broad-spectrum b...
|
|
WO/2021/055502A9 |
This invention provides a method of ameliorating the symptoms of, or treating a neurodegenerative disorder, Welander distal myopathy, psychiatric illness, or cancer in a mammal, the method comprising administering to the mammal an effect...
|
|
WO/2021/063177A1 |
Use of an insecticide in preventing or killing pests. An active ingredient of the insecticide is an isothiazolinone heterocyclic compound, having the structure formula as represented by formula I or formula II, R1 is hydrogen or alkyl, R...
|
|
WO/2021/059287A1 |
A method of oxygenating a benzylic C-H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze...
|
|
WO/2021/032057A1 |
The invention relates to an agricultural fungicide, the use thereof and a preparation method therefor. The agricultural fungicide has the chemical structure as shown in formula I or formula II. The agricultural fungicide is used for prev...
|
|
WO/2021/000867A1 |
Disclosed are an isoxazoline compound and an application thereof. The structure of the compound is as shown in general formula (I). The definitions of substituents in the formula are described in the description. The description also dis...
|
|
WO/2021/000865A1 |
An isoxazoline compound, a preparation method therefor and an application thereof. The compound has a structured as represented by general formula I. Also provided is use of the compound represented by general formula I as an insecticide...
|
|
WO/2020/255585A1 |
The present invention provides a method for purifying a compound that generates an acid when irradiated with active light or radiation, said method being capable of reducing the content of metal impurities, while having excellent recover...
|
|
WO/2020/254697A1 |
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...
|
|
WO/2020/247701A2 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are ...
|
|
WO/2020/201519A1 |
The present invention is directed to a novel process for purifying a recombinant polypeptide from a solution comprising one or more impurities, wherein the process is a chromatography process which uses saccharin. The present invention a...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/187440A1 |
The invention relates to aqueous benzisothiazoline-3-one-dispersions of sodium-1,2-benzisothiazoline-3-one-particles dispersed in water. The dispersions contain: (a) 15 wt.-% - 35 wt.-% sodium-1,2-benzisothiazoline-3-one and (b) ad. 100 ...
|
|
WO/2020/167893A1 |
The present invention is directed to the administration of a cannabinoid aerosol formulation using a soft mist inhaler (SMI) with reduced cannabinoid-related irritation and/or coughing. Described is an aerosol formulation comprising a ca...
|
|
WO/2020/147739A1 |
The present invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to lysophosphatidic acid receptor antagonists and a preparation method therefor. The compounds of the present invention have high ...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/121667A1 |
An ammonium salt having a saccharin anion, which is represented by formula (1), exhibits excellent thermal stability even though no halogen atom is contained therein. (In the formula, each of R1-R4 independently represents an alkyl group...
|
|
WO/2020/108538A1 |
An RORĪ³ inhibitor having sulfonyl structure, a preparation method thereof, and a pharmaceutical composition containing a plurality of compounds. The inhibitor has a structure represented by formula (I) or formula (V), wherein the compou...
|
|
WO/2020/092906A1 |
Provided herein are co-crystals comprising Compound 1 and a coformer. Pharmaceutical compositions comprising the co-crystals and methods for treating, preventing and managing disease are also disclosed.
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/084059A1 |
The present invention relates to N-nitrosaccharin of the general formula (I), wherein R is either a hydrogen (H) or a nitro group (NO2), its preparation and its use as nitrating agent.
|
|
WO/2020/070181A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and formula (A) are as defined in the description.
|
|
WO/2020/064564A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
|
|
WO/2020/056090A1 |
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...
|
|
WO/2020/040831A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.
|
|
WO/2020/034945A1 |
The present invention provides a method for preparing a cyclohexane derivative, comprising the following steps: (1) subjecting a compound SM01 and a compound SM02 or a salt thereof to a nucleophilic substitution reaction to obtain a comp...
|
|
WO/2020/034946A1 |
Provided is a method for preparing a cyclohexane derivative, the method comprising the following steps: subjecting a compound, 2-(4-(3,3-dimethylureido)cyclohexyl)acetaldehyde, represented by formula SM01 and a compound represented by fo...
|
|
WO/2020/032813A1 |
New 5-substituted 5-hydrazine-3-methylisothiazole-4-carboxylic acid derivatives with antitumor activity and a method for their preparation have been disclosed. The disclosed compounds inhibit the proliferation of MV 4-11 human bifenotypi...
|
|
WO/2020/002234A1 |
The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD)
|
|
WO/2020/006294A1 |
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
|
|
WO/2019/236890A1 |
The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SA...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/192988A1 |
The invention relates to a novel, single-stage method for producing and isolating 3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide (Isotianil), which has microbicidal and plant strengthening (host defence inducer) properties. In t...
|
|
WO/2019/190823A1 |
The application relates to pharmaceutically acceptable salts of [3-(4- {2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lH-imidazol-4-yl}-p
henoxy) -propyl]-diethylamine (Azeliragon) useful in the treatment of RAGE mediated diseases such as Alzh...
|
|
WO/2019/190999A1 |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...
|
|
WO/2019/178324A1 |
Provided herein are amino-benzoisothiazole and benzoisothiadiazole amide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic ...
|
|
WO/2019/174279A1 |
Provided herein are compositions and methods useful in the treatment of beta-lactam antibiotic resistant bacteria.
|
|
WO/2019/126567A1 |
Disclosed are heterocyclic-pyridinone analogs that are capable of inhibiting Nef-Hck and methods of treating viral infections such as, for example, HIV-1. This abstract is intended as a scanning tool for purposes of searching in the part...
|
|
WO/2019/090076A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/057142A1 |
The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)-N-((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl) amido)-2 oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isot...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/006359A1 |
The present disclosure relates to compounds that are capable of inhibiting the mitochondrial pyruvate carrier and promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorde...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/228984A1 |
The present invention relates to a novel process for preparing and isolating 3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide (Isotianil), which can be used as an active compound with microbicidal properties, wherein the amount of...
|
|
WO/2018/213770A1 |
Disclosed are therapeutic methods for treating cancer such as breast cancer.
|
|
WO/2018/211442A1 |
The present invention relates to 4-substituted amidine derivatives of the general formula (I), wherein A1-A4, D, L, Q, R7, R7' and integer's v and w have the meanings as defined in description. The invention further relates to methods fo...
|
|
WO/2018/185266A1 |
The invention relates to compounds of formula: wherein R1 to R7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/124185A1 |
The present invention provides a magnetic particle dispersion, said magnetic particle dispersion containing magnetic particles, an isothiazoline compound, and an aqueous medium.
|
